Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549
- 1 March 2006
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 58 (3) , 327-336
- https://doi.org/10.1211/jpp.58.3.0006
Abstract
Direct delivery of chemotherapeutic agents to the lung can increase both the drug concentration and exposure period to lung tumours. The objective of this study was to formulate docetaxel (DOC) into a metered dose inhaler (MDI), assess its aerodynamic characteristics and to evaluate the effect of celecoxib (CXB), a cyclooxygenase-2 (COX-2) inhibitor, on the in-vitro cytotoxicity and apoptotic response of aerosolized DOC against human lung adenocarcinoma cell line A549. A stable solution-type MDI formulation was developed with 0.25% DOC and 15% w/w ethyl alcohol using HFA 134a propellant. The formulation was evaluated for medication delivery, mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), percent throat deposition, respirable mass and respirable fraction. A six-stage viable impactor was used to assess the in-vitro cytotoxicity of DOC-MDI alone or in combination with CXB. Induction of apoptosis in A549 cells by DOC (non-aerosolized and aerosolized) in combination with CXB was evaluated by established techniques, such as caspase-3 estimation and terminal deoxynucleotidyl transferase-mediated nick end labelling (TUNEL) staining. The influence of different treatments on the expression of COX-2 and peroxisome proliferator-activated receptor-γ (PPAR-γ) in A549 cells was studied by RT-PCR. The DOC-MDI formulation had a MMAD of 1.58 μm, (GSD = 3.2) and a medication delivery of 80 μg/shot. DOC-MDI (one shot) in combination with CXB (10 μg mL−1) had a cell kill of more than 80% as determined by in-vitro cytotoxicity assay. The specific caspase-3 activity in A549 cells treated with DOC (0.01 μg mL−1) and CXB (10.0 μg mL−1) combination was 4 times higher than CXB and untreated control group, respectively. Further, TUNEL staining showed significant apoptosis of A549 cells treated with aerosolized DOC alone or in combination with CXB when compared with CXB and untreated cells. The RT-PCR experiments showed similar expression of COX-2 in both control and treated groups. PPAR-γ expression was increased in the combination treatment (0.01 μg mL−1 DOC and 10 μg mL−1 CXB) as compared with control (untreated), DOC (0.01 μg mL−1) and CXB (10 μg mL−1) treatments. Our results indicate the potential of inhalation delivery of DOC in the treatment of lung cancer.Keywords
This publication has 25 references indexed in Scilit:
- Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastasesInternational Journal of Cancer, 2005
- Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non–Small Cell Lung Cancer Xenograft ModelsClinical Cancer Research, 2004
- Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane‐based metered dose inhalersJournal of Pharmaceutical Sciences, 2004
- Cyclosporin A Aerosol Improves the Anticancer Effect of Paclitaxel Aerosol in MiceJournal of Aerosol Medicine, 2004
- Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsionsAAPS PharmSciTech, 2003
- Effect of chemopreventive agents on separate stages of progression of benzo[ ]pyrene induced lung tumors in A/J miceCarcinogenesis: Integrative Cancer Research, 2003
- PrefaceCurrent Cancer Drug Targets, 2003
- Evaluation of eicosanoids and NSAIDs as PPARγ ligands in colorectal carcinoma cellsProstaglandins, Leukotrienes & Essential Fatty Acids, 2003
- Inhalation Delivery of Anticancer Agents via HFA-Based Metered Dose Inhaler Using Methotrexate as a Model DrugJournal of Aerosol Medicine, 2002
- Inhalation exposure methodology.Environmental Health Perspectives, 1984